Literature DB >> 9739503

Rational antithrombotic therapy and prophylaxis in elderly, immobile patients.

E C van Gorp1, D P Brandjes, J W ten Cate.   

Abstract

The aging process is associated with increased coagulation and fibrinolysis parameters, resulting in an overall 'prethrombotic state'. This probably explains the increased baseline susceptibility of elderly patients to the development of thromboembolic disease. Additional factors such as major surgery or malignant disease multiply the risk of thromboembolism in this population. Even when adequate antithrombotic therapy is instituted, the mortality associated with thromboembolic disease remains considerable; this underlines the importance of adequate thromboembolic prophylaxis. At present, the use of low molecular weight heparins (LMWHs) in elderly immobile patients appears to be the most effective approach to prophylaxis. The use of compression stockings seems to be effective in the prevention of venous thrombosis, at least in moderate risk surgical patients. In patients undergoing orthopaedic surgery, additional prophylaxis (e.g. with an LMWH) is necessary. In the management of venous thrombosis, patients can initially be treated with a bodyweight-adjusted dosage of an LMWH. In patients with deep vein leg thrombosis or pulmonary embolism, oral anticoagulant therapy should be started as soon as possible, and should be continued for 6 months. However, before starting prophylaxis or therapy, an individual risk assessment should be performed in which the benefits and disadvantages are balanced. Most of the large trials that have studied the effects of thromboembolic prophylaxis have focused on postsurgical patients. However, it will be of great interest to develop more specific prophylactic and therapeutic regimens for different nonsurgical high risk subgroups of patients, particularly the elderly.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9739503     DOI: 10.2165/00002512-199813020-00006

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   4.271


  84 in total

1.  Which heparin for proximal deep-vein thrombosis?

Authors:  A W Lensing; M Prins; M M Koopman; H Buller
Journal:  Lancet       Date:  1992-08-01       Impact factor: 79.321

Review 2.  The coagulation cascade: initiation, maintenance, and regulation.

Authors:  E W Davie; K Fujikawa; W Kisiel
Journal:  Biochemistry       Date:  1991-10-29       Impact factor: 3.162

Review 3.  The changing pattern of venous thromboembolic disease.

Authors:  A T Cohen; R A Edmondson; M J Phillips; V P Ward; V V Kakkar
Journal:  Haemostasis       Date:  1996 Mar-Apr

4.  Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?

Authors:  D A Sandler; J F Martin
Journal:  J R Soc Med       Date:  1989-04       Impact factor: 5.344

5.  Hypercoagulability in centenarians: the paradox of successful aging.

Authors:  D Mari; P M Mannucci; R Coppola; B Bottasso; K A Bauer; R D Rosenberg
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

6.  Bleeding complications in oral anticoagulant therapy. An analysis of risk factors.

Authors:  F J van der Meer; F R Rosendaal; J P Vandenbroucke; E Briët
Journal:  Arch Intern Med       Date:  1993-07-12

7.  Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion.

Authors:  S Z Goldhaber; W D Haire; M L Feldstein; M Miller; R Toltzis; J L Smith; A M Taveira da Silva; P C Come; R T Lee; J A Parker
Journal:  Lancet       Date:  1993-02-27       Impact factor: 79.321

8.  Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis.

Authors:  S Siragusa; B Cosmi; F Piovella; J Hirsh; J S Ginsberg
Journal:  Am J Med       Date:  1996-03       Impact factor: 4.965

9.  Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.

Authors:  D P Brandjes; H Heijboer; H R Büller; M de Rijk; H Jagt; J W ten Cate
Journal:  N Engl J Med       Date:  1992-11-19       Impact factor: 91.245

10.  Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy.

Authors:  D L Clarke-Pearson; I S Synan; W M Hinshaw; R E Coleman; W T Creasman
Journal:  Obstet Gynecol       Date:  1984-01       Impact factor: 7.661

View more
  1 in total

Review 1.  Aspirin for the prevention of cardiovascular events in the elderly.

Authors:  Isabelle Mahé; Alain Leizorovicz; Charles Caulin; Jean-François Bergmann
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.